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Highlights 
• Educational and family-based interventions have had limited effects on child health 
outcomes or adherence. Parenting interventions are effective for reducing child 
behavioural and emotional problems, but have generally not been evaluated in child 
illness contexts. 
• Brief, group intervention led to fewer child illness behaviour problems, improved 
parental self-efficacy and better parent and family health related quality of life HRQL, 
and improved child health.  
• The study demonstrates that improved parenting can lead to better child health outcomes. 
• Parents’ needs for parenting and child behaviour support should be routinely assessed by 
clinicians. Parenting intervention should be considered as an element of chronic health 
condition management to improve child health outcomes.   
 
 
 
Keywords:  
Parenting, behavioural family intervention, asthma, eczema, atopic dermatitis, chronic 
disease, child, self-efficacy, child behaviour, health behaviour  
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Abstract  
 
Childhood chronic health conditions have considerable impact on children. We aimed to test 
the efficacy of a brief, group-based parenting intervention for improving illness-related child 
behaviour problems, parents’ self-efficacy, quality of life, parents’ competence with 
treatment, and symptom severity. A 2 (intervention vs. care as usual) by 3 (baseline, post-
intervention, 6-month follow-up) design was used, with random group assignment. 
Participants were 107 parents of 2- to 10-year-old children with asthma and/or eczema. 
Parents completed self-report questionnaires, symptom diaries, and home observations were 
completed. The intervention comprised two 2-hour group discussions based on Triple P. 
Parents in the intervention group reported (i) fewer eczema-related, but not asthma-related, 
child behaviour problems; (ii) improved self-efficacy for managing eczema, but not asthma; 
(iii) better quality of life for parent and family, but not child; (iv) no change in parental 
treatment competence; (v) reduced symptom severity, particularly for children prescribed 
corticosteroid-based treatments. Results demonstrate the potential for brief parenting 
interventions to improve childhood chronic illness management, child health outcomes, and 
family wellbeing. Effects were stronger for eczema-specific outcomes compared to asthma-
specific outcomes. Effects on symptom severity are very promising, and further research 
examining effects on objective disease severity and treatment adherence is warranted. 
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Introduction 
Chronic child health conditions are common (Van Cleave, Gortmaker, & Perrin, 2010) and 
children experience more behavioural, emotional and academic problems compared to 
healthy children (Pinquart, 2012; Pinquart & Shen, 2011; Pinquart & Teubert, 2012). The 
majority of conditions require daily management, yet non-adherence with treatment and 
prevention is around 50% (Morton, Everard, & Elphick, 2014).  
Existing health care focuses largely on a medical education model which has shown 
limited success in improving adherence (Dean, Walters, & Hall, 2010; Ersser et al., 2014) 
and family-based approaches have also shown limited effects (Eccleston, Palermo Tonya, 
Fisher, & Law, 2012; Law, Fisher, Fales, Noel, & Eccleston, 2014). The theoretical and 
empirical literatures provide compelling evidence that parenting plays a central role in 
children’s health outcomes (Morawska, Calam, & Fraser, 2015; Wood et al., 2008); yet, 
current approaches to childhood illness management do not target parenting (Law et al., 
2014). Parent and family factors impact on illness onset (Mrazek et al., 1999), and disease 
course (Rohan et al., 2014), and parents of chronically ill children engage in different 
parenting practices compared to parents of healthy children (Holmbeck et al., 2002; Pinquart, 
2013).  
Parenting practices are readily modifiable and may serve as a pathway to better parenting 
and child outcomes, and potentially to better health outcomes (Morawska, Calam, et al., 
2015). Behavioural parenting interventions are recognised as best practice in the treatment of 
parenting and child behaviour difficulties (O'Connell, Boat, & Warner, 2009), however these 
have rarely been applied in the context of child illness management (Kirk et al., 2012). 
Recent studies have demonstrated some positive, albeit mixed, effects of parenting 
intervention for child chronic conditions (Clarke, Calam, Morawska, & Sanders, 2014; 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Doherty, Calam, & Sanders, 2013; Lohan, Morawska, & Mitchell, 2015; Sassmann, de Hair, 
Danne, & Lange, 2012; Westrupp, Northam, Lee, Scratch, & Cameron, 2015) providing 
promising signs that this approach may add value to existing health services.  
To date interventions for parents of children with chronic health conditions have focussed 
on a medical model, and the evaluation of psychosocial interventions has been limited. Those 
parenting interventions which have been evaluated have had mixed evidence, potentially 
because they have generally not tailored programs for children with chronic health conditions 
(Westrupp et al., 2015); used interventions with multiple sessions which are burdensome for 
parents to attend (Sassmann et al., 2012; Westrupp et al., 2015)} or included only a small 
parenting component within a more complex intervention (Lohan et al., 2015). Thus, our aim 
was to test the efficacy of a brief, group parenting intervention for parents of children with 
asthma and/or eczema, on parents' confidence with illness management, child illness-related 
behaviour problems, quality of life, symptom severity and parent competence in relation to 
administering their child’s treatment. Our focus was on asthma and eczema as these are the 
two most common childhood chronic health conditions in Australia, affecting 20% and 17% 
of Australian children respectively (Asher et al., 2006). Australian prevalence rates for 
asthma and eczema are comparable to those seen in the UK (21% and 16%, respectively), and 
exceed those reported for most regions of North America (e.g., Canada, 18.2%, 12%), Europe 
(e.g., Germany, 13%, 8%), the Asia-Pacific (e.g., Hong Kong, 9% and 5%), and Africa (e.g., 
Nigeria, 6% and 5%) (Asher et al., 2006). We chose a heterogeneous illness group because 
these conditions commonly co-occur; there is limited evidence of a link between particular 
health conditions and specific behavioural and emotional problems, but rather a more general 
relationship between maladjustment and childhood chronic illness, and; practically it is easier 
for health services to deliver intervention to more heterogonous groups  (Morawska, Calam, 
et al., 2015). We expected that participation in the parenting intervention would lead to: (i) 
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fewer child illness-related behaviour problems; (ii) improved parental illness management 
self-efficacy; (iii) improved child, parent and family HRQL; (iv) better parental treatment 
competence; and (v) reduced symptom severity compared to care as usual.  
This study is part of a larger trial, and general parenting and child behaviour, and parent 
and child adjustment outcomes, are reported separately (Morawska, Mitchell, Burgess, & 
Fraser, 2015). This paper focuses specifically on health-related outcomes of illness 
management, symptom severity, and HRQL. 
Methods 
A 2 (Intervention vs. Care as Usual[CAU]) x 3 (time: pre-intervention[T1], post-
intervention[T2], 6-month follow-up[T3]) design was used. Permission was granted by 
relevant ethics review committees. Recruitment was across the Brisbane metropolitan region 
via school and healthcare settings. Study information to be distributed in school newsletters 
was emailed to all primary schools and child care centres within a 50km radius of the city 
centre. Posters and brochures were sent to all family medical practices and paediatricians, 
dermatologists, and respiratory physicians in Brisbane, as well as the emergency departments 
and outpatients’ clinics of Brisbane’s two specialist children’s hospitals.   
    Recruitment was from July 2011 to July 2013. Parents of 2- to 10-year-old children with 
asthma and/or eczema, with concerns about the child’s behaviour, emotions, or illness 
management were eligible. Confirmation of diagnosis was obtained from the children’s 
treating doctors. Families were ineligible if children had a disability or developmental 
disorder, or parents were receiving professional help for children’s behaviour difficulties, or 
psychological help or counselling for themselves. Where both parents agreed to participate in 
the study, the parent who assumed primary responsibility for the child’s health care was 
designated as the “primary” participant, and completed all study assessment. Secondary 
participants completed parent-report questionnaires only; these results are reported elsewhere 
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(Morawska, Mitchell, et al., 2015). Where families had multiple children with asthma and/or 
eczema, parents selected one child to focus on for the purposes of the study. 
Procedure 
Parents received study information, completed eligibility screening with the trial coordinator, 
and consented to participate via the study website. Prior to randomisation, participants 
completed T1 assessment, consisting of: (i) parent-report questionnaires, in online (n=95) or 
hardcopy (n=12) format depending on parent preference; (ii) two weeks of symptom 
monitoring; and (iii) participation in an observation of a typical home treatment session. 
    Allocation was by block randomisation, using computer-generated randomly-selected 
block sizes (4, 6, or 8 participants per block) and random group allocation within each block. 
An external researcher generated random allocation sequences, and prepared sequentially-
numbered opaque envelopes to conceal group allocation. Envelopes were assigned by a 
research assistant in the order families completed T1 assessment. Neither researchers nor 
participants were blinded to intervention group.  
    Families assigned to the Intervention group attended the intervention and repeated 
assessments at 4 weeks (T2) and 6 months (T3) post-intervention. Families assigned to CAU 
repeated assessments at 6 weeks (T2) and 6 months (T3) post-enrolment. On enrolment into 
the study all families, irrespective of group allocation, were instructed to continue their 
child’s usual medical management, for example, attending appointments with their child’s 
doctor/s and other health care professionals, and continuing to follow the child’s medical 
management plan as normal. CAU families attended the program after completing T3 
assessment.  
Intervention 
The intervention consists of two interactive 2-hour group discussion sessions, Positive 
Parenting for Healthy Living (Morawska & Sanders, 2011), and draws on theoretical 
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principles that form the basis of Triple P (Sanders, 2012). Proximal targets of the intervention 
are parenting skill and confidence relating to both general child behaviour, and specific to 
illness management; and parenting practices and family stress, which constitute direct and 
indirect pathways of parenting impact on child health and wellbeing (Wood et al., 2007). 
Teaching methods included didactic instruction, video modelling, active skills training, and 
homework tasks. 
The intervention targets parents of 2-10 year-old children and strategies and examples 
are tailored to specific developmental and other needs during sessions. This may involve 
asking parents to consider how a strategy applies to their child, for example by reflecting how 
involving a child in their illness management differs for a 3-year-old versus and 10-year-old. 
The underlying principles for each strategy are the central focus, with examples used to 
illustrate flexible application. 
    The first session focuses on strategies to empower parents to prevent and manage problem 
behaviours and ensure that illness prevention and management plans are implemented 
appropriately. Topics include continuing regular activities; having realistic expectations; 
reducing stress; helping siblings cope; condition-specific management steps; involving the 
child; communicating with caregivers; keeping track of symptoms; and being prepared for 
emergencies. The second session introduces the principles of positive parenting in the context 
of child chronic illness management, to promote positive parenting practices, assist parents to 
develop effective disciplinary methods, and help create environments conducive to caring 
parent-child relationships. Key content includes causes of behaviour problems in children 
with chronic illnesses; parenting traps; use of routines to improve treatment management; 
preventing and managing anxiety; and behavioural strategies, including descriptive praise, 
positive attention, giving clear instructions, consequences, and behaviour charts. The 
strategies are presented with examples focusing on how they can be used in the context of 
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illness management. Examples of how strategies would be implemented in the childhood 
chronic illness context were tailored depending on the specific concerns of parents in the 
group (e.g. medication/treatment refusal, child anxiety, sibling/peer conflict).  
    Program content is not condition-specific; rather, it addresses issues common to most 
childhood chronic health conditions. Condition-specific information was limited to take-
home tip sheets providing accurate, up-to-date information on disease aetiology and 
management (1 for asthma, 1 for eczema), and brief videos demonstrating key management 
steps (1.5 minutes for asthma, and 3.5 minutes for eczema) that were played during the first 
session. Children frequently had older sibling/s with asthma, eczema, or both conditions; 
thus, the vast majority of parents wanted information about both conditions, and all sessions 
included group discussions about both conditions regardless of group composition.  
     Eighteen discussion groups were held at a university psychology clinic in metropolitan 
Brisbane, Australia, between August 2011 and December 2013. Groups comprised an 
average six parents (M=6.56, SD=3.54) from four families (M=4.44, SD=2.60). Sessions were 
facilitated by 10 accredited Triple P practitioners (psychologists or nurses). 
Assessment  
The Family Background Questionnaire (Sanders & Morawska, 2010) was used to assess 
demographic variables.  
    Primary outcomes. Parent-report questionnaires. The modified Parents’ Self-Efficacy 
with Eczema Care Index (PASECI; α=.96 Charman, Venn, & Williams, 2004) and the 
Asthma Parent Tasks Checklist (APTC) Confidence scale (α=.93; Morawska, Stelzer, & 
Burgess, 2008) assessed parents’ self-efficacy for performing tasks necessary to manage their 
child’s eczema or asthma.  
    The Eczema Behaviour Checklist (EBC; Mitchell, Morawska, Sillar, & Fraser, 2015) and 
the Asthma Behaviour Checklist (ABC; Morawska et al., 2008)  assessed the extent to which 
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parents experienced child behaviour problems related to eczema (EBC Extent; α=.92) or 
asthma (ABC Extent; α=.93), and their level of confidence with managing these behaviours 
(EBC Confidence, α=.95; ABC Confidence, α=.98).  
    The PedsQL4.0: Pediatric Quality of Life Generic Core Scale (Varni, Seid, & Kurtin, 
2001) assessed child health-related quality of life (HRQL; α=.82). The PedsQL Family 
Impact Module (Varni, Sherman, Burwinkle, Dickinson, & Dixon, 2004) assessed parent 
HRQL (α=.93) and family functioning (α=.92). 
    Secondary outcomes. Symptom monitoring. Parents recorded symptoms daily for 2 
weeks at each time-point:  whether (yes/no) skin was itchy, bleeding, cracked, flaking, rough, 
weeping or oozing, and sleep disturbance, and; number of asthma episodes, whether any were 
moderate-severe (i.e. >2 hours; interfered with play/school/sleep; led to shortening of normal 
activity, seeing a doctor, or going to hospital). Weekly scores were averaged to calculate 
mean eczema severity (Patient-Oriented Eczema Measure; POEM; Mitchell & Fraser, 2011), 
mean asthma episodes/week, and mean number of days/week with moderate-severe episodes.  
    Observation. A routine at-home medical management session was observed at each time-
point, lasting a mean 4.93 minutes at T1 (SD=4.49, range 0.5-28.5). For eczema, parents 
applied their child’s usual topical treatments and/or wet-wraps. For asthma, parents 
administered two doses of a placebo metered dose inhaler (MDI).   
     Medical management sessions were videotaped, and competence with providing treatment 
was assessed by trained research assistants blind to condition. For eczema management, 
parents scored a maximum 11 points for applying adequate moisturiser; for asthma 
management, parents scored a maximum 5 points for correctly administering the MDI. A 
random 25% of sessions were assessed by a second research assistant. Intra-class correlations 
(ICC) indicated excellent inter-rater agreement for eczema (ICC=.97) and asthma (ICC=.76) 
treatment competence scores.  
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Protocol Adherence 
The intervention was delivered according to a standardised manual and treatment delivery 
protocol. Protocol adherence checklists completed by group facilitators indicated 100% of 
content was covered. Groups were digitally recorded and 25% (n=5) were independently 
coded, with 97.7% agreement between facilitators and an independent rater. No parents 
reported receiving additional parenting support during the study period.  
Statistical Analyses 
To detect a medium effect size (d=.50), 128 families were needed to provide 80% power with 
a type 1 error of 5% (two-tailed) for the primary hypotheses to be tested. Longitudinal 
intention-to-treat analyses were performed using mixed-model repeated-measures (MMRM) 
linear regression models in SPSS. In all, 7.2% of data were missing completely at random, 
and the full information maximum likelihood approach to handling missing data was applied. 
First, models containing fixed and random effects of time (T1/T2/T3) were assessed for a 
main effect of time (Model 1). Next, fixed effects of group and group-by-time interactions 
were added, and significant interaction terms indicated significant intervention effects (Model 
2). To interpret direction of intervention effects, follow-up contrasts using models with fixed 
and random effects of time as predictors were run separately for Intervention and CAU 
groups (Models 3 and 4), and t-tests compared rate of change (regression parameter estimate 
for time) between groups. Where data variability was insufficient to support inclusion of 
random effect of time, the random effect was excluded from all four models. Analysis was 
conducted for all participants by originally assigned group. One extreme outlier was detected 
in each group for the number of asthma episodes/week at T3, and excluded from analyses 
using this variable.     
    On the assumption that intervention-driven improvements in symptom severity would most 
likely arise from improved adherence to the child’s treatment regimen, we also conducted 
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exploratory post-hoc sub-group analyses to compare change in symptom severity for those 
children whose treating doctors had prescribed preventer medications or topical steroids for 
asthma or eczema treatment, respectively, and those whose doctors had not. We anticipated 
greater improvement where children had been prescribed corticosteroid medications, which 
are typically administered once or more daily, as these parents would have more frequent 
opportunities to face resistance to treatment from their child, and improved adherence should, 
theoretically, result in the greatest improvements in symptom severity post-intervention. 
Results 
Sample 
Of 164 parents who expressed interest, 148 met eligibility criteria, and 107 consented to 
participate, completed T1 assessment, and were randomly allocated. Progress of participants 
through the study is detailed in Figure 1. Baseline characteristics of participants are provided 
in Table 1 and there were no significant differences between groups at baseline.  
Age at diagnosis was birth-8 years for eczema and 6 months-8 years for asthma. For 
eczema, 90% were diagnosed by age 2, and 68% by age 1. For asthma, 60% were diagnosed 
by age 2. Doctors reported prescribing topical corticosteroids for 70%(59) of children with 
eczema and inhaled corticosteroids for 68%(32) of children with asthma. 
    For eczema, mean POEM scores at T1 classified children’s eczema as clear/almost clear 
(2%, 2), mild (11%, 9), moderate (54%, 45), severe (27%, 22), or very severe (6%, 5) 
(POEM M=13.76, SD=5.90, range 0-28). During T1 asthma symptom monitoring, 70%(30) 
experienced ≥1 asthma episodes (M=2.35/week, SD=2.88, range 0-23), and 18%(8) had ≥1 
day/week where an episode lasted >2 hours (M=0.27, SD=0.72). On ≥1 day/week, asthma 
interfered with activity/play/school/sleep for 66%(29) (M=1.44, SD=1.72), shortened normal 
activity for 48%(21) (M=1.01, SD=1.52), and led to seeing a doctor for 14%(6).  
Attrition  
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Of parents allocated to Intervention, 40(77%) attended both sessions, 5(10%) attended one 
session, and 7(13%) did not receive the intervention. Of the final sample (n=107), 95(89%) 
completed T2 assessment: of the Intervention group parents, 5 did not attend the sessions and 
withdrew prior to T2, 1 was unable to be contacted after initial enrolment, and 2 attended 
groups but withdrew prior to T2. A further 2 parents withdrew prior to T3. In the CAU group, 
4 parents withdrew before T2, and another 6 families withdrew prior to T3. The proportion of 
participants lost to follow-up did not differ significantly between Intervention (10/52) and 
CAU (10/55) groups, χ2(1,n=107)=0, P=1.00. No adverse effects, concerns, or unintended 
consequences were identified. 
Intervention Effects 
Means, standard deviations, and effect sizes (Cohen’s d) for eczema, asthma, and HRQL 
outcomes are presented in Tables 2, 3, and 4, respectively. Results of MMRM analyses are 
presented in Table 5.  
    Parents’ self-efficacy. Time predicted improvement in confidence with performing 
eczema management tasks (PASECI) (see Table 5). A significant time-by-group interaction 
indicated a significant intervention effect, such that the Intervention group showed greater 
improvement over the 6 months post-intervention compared to the CAU group, who showed 
no significant change.  
Conversely, time did not predict change in confidence with performing asthma 
management tasks (APTC Confidence) (see Table 5). The time-by-group interaction was not 
significant, and there was no difference between groups on rate of change, with neither group 
showing significant change.  
    Child behaviour. Time predicted improvement in extent of eczema-related behaviour 
difficulties (EBC Extent), as well as parents’ self-efficacy for dealing with them (EBC 
Confidence) (see Table 5). Time-by-group interactions were significant, indicating significant 
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intervention effects for both Extent and Confidence. Improvement in EBC Extent scores was 
greater for the Intervention group, although CAU also demonstrated a smaller but statistically 
significant improvement. Improvement in EBC Confidence scores was also greater in the 
Intervention group, and only the Intervention group showed significant improvement.  
Conversely, time did not predict change in extent of asthma-related behaviour difficulties 
(ABC Extent) or parents’ self-efficacy for dealing with them (ABC Confidence) (see Table 
5). Time-by-group interactions were not significant, and follow-up contrasts found no 
difference between groups on rate of change. Notably, mean item scores for behaviour 
problems at baseline were somewhat higher for eczema-related behaviours (EBC Extent; 
M=3.57, SD=1.11) compared to asthma-related behaviours (ABC Extent; M=2.13, SD=0.97). 
Parents’ mean confidence scores at baseline for managing eczema (EBC Confidence; 
M=7.10, SD=1.59) were somewhat lower compared with managing asthma (ABC 
Confidence; M=8.35, SD=1.77).  
    HRQL. Time predicted improvement in children’s HRQL (PedsQL Total) (see Table 5). 
The time-by-group interaction was not significant, indicating no significant intervention 
effect. Both groups showed significant improvement, with no significant difference in rate of 
change between groups. 
    Time predicted improvement for both PedsQL Parent HRQL and Family Functioning 
scores (see Table 5). Time-by-group interactions were significant, indicating significant 
intervention effects for both variables. The Intervention group showed greater improvement 
for both measures compared to CAU, which did not show significant change over time. 
    Symptom severity. Time did predict decrease in eczema severity (POEM scores), and the 
time-by-group interaction was not significant (p=.052) (see Table 5). Decrease in POEM 
scores was greater for the Intervention group compared to CAU, where there was no 
significant change. At T2 and T3, 39% (12/31) and 56% (18/32) of the Intervention group 
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demonstrated clinically significant improvement (decrease of ≥3.4 points) (Schram et al., 
2012) compared to 22% (9/41) and 34% (13/38) of the CAU group. Exploratory sub-group 
analyses (see Table 6) showed that for children prescribed topical corticosteroids 
(Intervention n=23, CAU n=36) the time-by-group interaction was significant, and the 
decrease in eczema severity was significantly greater for the Intervention group, with large 
effect size (d=.95, 95%CI 0.36-1.54). Conversely, for children not prescribed topical 
corticosteroids (Intervention n=15, CAU n=10), the time-by-group interaction was not 
significant, and there was no significant change for either group (see Table 6). Plots of 
regression slopes for change in eczema severity (POEM scores) over time for Intervention 
and CAU sub-groups are presented in Figure 2.  
Time did not predict change in mean asthma episodes/week (see Table 5). The time-by-
group interaction was significant, indicating a significant intervention effect. The decrease in 
asthma episodes was greater for the Intervention group compared to CAU, who showed no 
significant change. Sub-group analyses (see Table 6) showed that for children prescribed a 
preventer (Intervention n=14, CAU n=16) there was a significant time-by-group interaction, 
such that the Intervention group showed a significant decrease in asthma episodes compared 
to CAU where there was no significant change, with large effect size (T1-T3 d=1.19, 95% CI 
0.36-2.02). Conversely, for children not prescribed a preventer (Intervention n=9, CAU n=6) 
the time-by-group interaction was not significant, and there was no significant change for 
either group (see Table 6). Plots of regression slopes for change in asthma episodes per week 
over time for Intervention and CAU sub-groups are presented in Figure 3. 
    Time did predict decrease in mean days/week where asthma episodes were moderate-
severe (see Table 5). The time-by-group interaction was not significant (p=.07). There was a 
significant decrease in the Intervention group, but no change for CAU, and the difference in 
rate of change between the groups approached significance (p=.08) (see Table 5).  
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Exploratory sub-group analyses (see Table 6) showed that for children with asthma 
prescribed a preventer, the time-by-group interaction was not significant (p=.051), and the 
Intervention group showed a significant decrease in days with moderate-severe asthma 
episodes compared to CAU, where there was no significant change. The difference between 
groups was not significant, with a medium effect size (T1-T3 d=.67, 95%CI -.11-1.46). 
Conversely, for children not prescribed a preventer the time-by-group interaction was not 
significant, and there was no significant change for either group (see Table 6). 
    Observed parent competence with management. Time did not predict change in 
scores for eczema or asthma management competence, and time-by-group interactions were 
not significant, indicating no intervention effect (see Table 5). There were no differences by 
group on rate of change of scores, which did not change significantly over time for either 
group. 
Discussion 
Childhood illness management rarely targets parenting practices or confidence; thus, the 
results of this trial are particularly important. While intervention effects depended to an 
extent on whether children had asthma or eczema, parents reported greater confidence with 
illness management, fewer child behaviour difficulties, as well as better parent and family 
quality of life (Table 5). There were also improvements in clinical outcomes for children with 
both asthma and eczema, particularly for those children prescribed corticosteroid-based 
treatments (Table 6).     
There were some inconsistencies in the findings worthy of note. Intervention effects for 
parent confidence and child behaviour held only for eczema outcomes, and not asthma 
outcomes. Although the relatively smaller size of the asthma sub-sample may have limited 
our ability to detect significant effects, particularly in the case of parents’ asthma 
management self-efficacy, the effect sizes for the asthma-specific child behaviour extent and 
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confidence were nevertheless much smaller compared to those for eczema (Tables 3 and 2, 
respectively). Equivocal results have previously been reported for parenting intervention in 
the context of asthma (Clarke et al., 2014). In this study, at baseline parents had more 
confidence with managing asthma behaviours than eczema behaviours, leaving less room for 
improvement. Furthermore, eczema management tends to be more time consuming and 
complicated, thus differential intervention effects may be due to the heterogeneity of the 
children’s presentation and resulting parenting challenges. Finally, there is growing evidence 
that preventive (steroid) interventions are not effective for the majority of children with viral 
induced wheeze aged <6 years, thus diluting the impact of any intervention designed to 
enhance treatment competence on treatment outcomes in younger children (Bush, Grigg, & 
Saglani, 2014). There were significant improvements in child HRQL for Intervention and 
CAU groups, resulting in no significant difference between Intervention and CAU groups 
(Table 5). The effect size for this result was very small at time 3 (d=.15, see Table 4), perhaps 
reflecting small improvements over time as children mature and become more adept at 
managing the impact of their illness. There was no change in observed treatment competence 
(Table 5), although this was not a direct target of the intervention, and points to the need for 
further parent education and training in effective treatment.  
Notably, symptom severity improved, and effects were more pronounced for children with 
prescribed corticosteroid medication (Figures 2 and 3). These analyses were conducted on the 
assumption that intervention-driven improvements in symptom severity would most likely 
arise from improved adherence to the child’s treatment regimen. We anticipated greater 
improvement where children had been prescribed corticosteroid medications, as these parents 
would have more frequent opportunities to face resistance to treatment from their child. With 
more opportunities to practice and implement parenting strategies, the impact on adherence 
should be greater, resulting in the more improvements in symptom severity post-intervention. 
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Effect sizes were in the moderate-high range, and highest at 6-month follow-up (Tables 2 and 
3). Analyses were considerably underpowered, as only a proportion of children had each 
condition. Importantly, for children with asthma in the intervention condition at T3 the 
number of episodes/week had reduced below one, while it had remained above the guideline 
level of two (Global Initative for Asthma, 2015) for children in CAU (Table 3). These results 
are very promising and point to the importance of conducting further research specifically 
examining treatment adherence and health outcomes in children.        
The comparatively high rate of participation, good session attendance, and modest attrition 
demonstrates that even when faced with the additional pressure of managing a child with a 
chronic condition, parents can be engaged and retained in a brief, group parenting program 
specific to childhood illness and behaviour management. This is an important finding because 
translation and dissemination of parenting programs has been constrained by poor uptake and 
fragmented parental involvement (Hindman, Brooks, & van der Zwan, 2012). The program 
was delivered over two, short sessions, held a week apart on weeknights or Saturdays to 
reduce barriers to participation. It may be that the brief time commitment to the intervention 
may have eased many of the barriers parents often experience to participating in any 
parenting program (e.g., finding childcare, timing of sessions, time commitment).  
Some caution should be applied to interpretation of findings as a number of limitations are 
acknowledged. Firstly, measures were well validated, but the study relied largely on parent-
report. Future studies should focus on objective assessment of both treatment adherence and 
illness severity. Future trials should also test for any impact of the intervention on patterns of 
health care usage (e.g. routine medical reviews, emergency presentations) as this was beyond 
the scope of the current study. The design of this trial did not allow for specific testing of 
mechanisms that might contribute to change. The precise relationship between improved 
parenting and child health outcomes is not well understood, and the effect of augmenting the 
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standard behavioural parenting program with strategies to manage resistant behaviours 
remains to be tested. Finally, families were unselected, and generally of higher socio-
economic status; thus, generalisability of these findings remains to be tested.  
Conclusion 
Our study indicates that a brief parenting intervention tailored for parents of chronically ill 
children can lead to significant benefits in parental illness management self-efficacy, child 
behaviour and family quality of life, however, this may depend on the initial type and 
severity of the condition. Effects differed by child illness condition, suggesting the need to 
explore moderators of outcome and potential pathways of effect depending on the nature of 
the illness and the corresponding parenting tasks. While underpowered, our study also 
provided strong evidence for reductions in symptom severity. This is a highly important 
finding as it demonstrates that an intervention focused on improving parenting can lead to 
improvements in child health outcomes.  
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Figure 1. CONSORT diagram of flow of participants 
 
Enrolment Assessed for eligibility (n=164) 
Excluded (n=57) 
 Not meeting inclusion criteria (n=16) 
 Declined to participate (n=4) 
 Never completed T1 assessment (n=37) 
Randomised (n=107) 
Allocated to Intervention (n=52) 
 Received allocated intervention (n=40) 
 Attended one session only (n=5) 
 Did not receive allocated intervention (n=7) 
o Lack of time/family commitments (n=6) 
o Not contactable (n=1) 
Allocated to Care as Usual (n=55) 
Allocation 
Lost to T2 follow-up (n=8) 
 Lack of time/family commitments (n=5) 
 No longer wish to participate (n=2) 
 Not contactable (n=1) 
Lost to T2 follow-up (n=4) 
 Lack of time/family commitments (n=3) 
 No longer wish to participate (n=1) 
4 Week Follow-Up 
Lost to T3 follow-up (n=2) 
 No longer wish to participate 
Lost to T3 follow-up (n=6) 
 No longer wish to participate (n=4) 
 Child diagnosed with ADHD (n=1) 
 Not contactable (n=1) 
6 Month Follow-Up 
Analysed (n=55) Analysed (n=52) 
Analysis 
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Table 1. Demographic and clinical characteristics of participants by group 
 
Variables  Intervention (n=52) Care as Usual (n=55)  
  M (SD) M (SD) t 
     
Parent’s age (years)  36.69 (5.20) 37.84 (4.94) 1.05 
     
Child’s age (years)  5.02 (2.14) 5.05 (2.26) 0.17 
     
Child’s age at  
    diagnosis (years) 
Eczemaa 0.79 (1.05) 1.04 (1.63) 0.84 
Asthmab 2.79 (1.69) 2.55 (1.66) -0.53 
     
Symptom severity at  
   baseline 
Asthma episodes / week 2.38 (3.33) 2.32 (2.44) -0.07 
Eczema severity (POEM)c        13.46 (6.37)        14.01 (5.54) 0.42 
     
  % (n) % (n) χ2 
     Clear / almost clear  5 (2)             - -d 
     Mild 13 (5)           9 (4)  
     Moderate 45 (17)         62 (28)  
     Severe 34 (13)         20 (9)  
     Very severe 3 (1)           9 (4)  
     
Diagnoses Asthma 48 (25) 42 (23) 0.21 
     Eczema 75 (39) 84 (46) 0.75 
 Both asthma and eczema 26 (14) 23 (12) 0.00 
     
Previous hospital 
    separation (yes)     
Eczemaa 19 (7) 11 (5) 0.48 
Asthmab 33 (7) 48 (10) 0.40 
     
Child’s sex Male 52 (27) 53 (29) 0.00 
 Female 48 (25) 47 (26)  
     
Ethnicity Caucasian 87 (45) 84 (46) 0.25 
 Asian   8 (4) 13 (7)  
 Pacific Islandere   2 (1)   -  
 Not specifiede   4 (2)   4 (2)  
     
Household Original family 89 (46) 76 (42) 1.91 
 Sole parent / step family 11 (6) 24 (13)  
     
Parent’s relationship 
    to child 
Mother 92 (48) 96 (53) 0.24 
Father   8 (4)   4 (2)  
     
Parent’s education High school or less 12 (6) 24 (13) 8.34 
 Trade/college 23 (12)   9 (5)  
 University degree 52 (27) 42 (23)  
 Postgraduate degree 14 (7) 26 (14)  
     
Relationship status Married/de facto 90 (47) 78 (43) 2.14 
     Separated/divorced/single   10 (5)  22 (12)  
         
Parent’s employment Full-time/part-time 67 (35) 62 (34) 0.15 
     Not working/job seeking 33 (17)  38 (21)  
     
Able to meet  
    essential expensesf 
Yes  81 (42) 86 (47) 0.16 
No 17 (9) 13 (7)  
     Don’t knowe 2 (1)   2 (1)  
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After expenses can  
    afford 
Not much 15 (8) 16 (9) 0.49 
Some things 54 (28) 47 (26)  
 Most things 31 (16) 36 (20)  
     
Abbreviation: POEM, Patient Oriented Eczema Measure (0-2 = clear / almost clear; 3-7 = mild; 8-16 = 
moderate; 17-24 = severe; 25-28 = very severe). 
a
MIssing
 
data for Intervention n = 3, Care as Usual n = 2. 
b
MIssing data for Intervention n = 4, Care as Usual n 
= 2. 
c
Missing data for Intervention = 1, Care as Usual = 1. 
d
Chi-square test for independence not performed 
as 6 expected cell frequencies <5. 
e
Cases
 
excluded from chi-square test for independence as observed 
frequencies <5. 
f
Able to meet essential household expenses during the past 12 months. 
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Table 2. Means and standard deviations for eczema outcomes by treatment condition, and effect sizes 
 Intervention (n=39) Care as Usual (n=46) Effect sizea 
T1 T2 T3 T1 T2 T3 T1-T2 T1-T3 
Measure M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
d 
[95% CI] 
d 
[95% CI] 
Self-efficacy with eczema 
managementb 
7.05 8.01 8.06 7.71 7.93 8.01 0.54 0.49 
(1.57) (1.26) (1.70) (1.63) (1.33) (1.16) [0.08-1.00] [0.01-0.97] 
 38 34 32 46 43 37   
Self-efficacy with eczema 
behaviour managementc 
166.45 200.38 207.03 186.65 196.40 191.14 0.64 1.00 
(38.06) (29.59) (31.93) (39.20) (31.80) (45.04) [0.18-1.10] [0.50-1.50] 
 38 34 32 46 43 37   
Extent of eczema 
behaviour difficultiesd 
94.58 78.62 63.78 84.87 77.19 74.68 0.19 0.65 
(28.95) (28.61) (24.99) (26.37) (28.60) (26.18) [-0.26-0.64] [0.16-1.13] 
 38 34 32 46 43 37   
Eczema symptom severitye 13.46 10.97 9.31 14.01 13.52 12.11 0.42 0.55 
(6.37) (6.12) (6.03) (5.54) (5.99) (5.43) [-0.05-0.88] [0.07-1.02] 
 38 31 32 45 41 38   
Competence with eczema 
management (observed)f 
6.69 8.41 7.63 7.09 6.93 6.59 0.17 0.34 
(4.27) (3.43) (4.01) (4.13) (3.91) (4.10) [-0.30-0.65] [-0.17-0.85] 
 39 29 27 46 41 32   
Abbreviations: T1, time 1 (baseline); T2, time 2 (post-intervention); T3, time 3 (6-month follow-up); CI, confidence interval. 
a
Effect sizes (Cohen’s d) represent the T1-T2 change in Intervention group minus the T1-T2 change in Care as Usual group, divided by the 
pooled T1 standard deviation for the measure. 
b
Modified Parental Self-Efficacy with Eczema Care Index (PASECI) (possible range 0-10). 
c
Eczema Behaviour Checklist – Confidence scores (possible range 25-250). 
d
Eczema Behaviour Checklist – Extent scores (possible range 25-
175). 
e
Patient-Oriented Eczema Measure (possible scores 0-28). 
f
Possible scores 0-11. 
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Table 3. Means and standard deviations for asthma outcomes by treatment condition, and effect sizes 
 Intervention (n=25) Care as Usual (n=23) Effect sizea 
T1 T2 T3 T1 T2 T3 T1-T2 T1-T3 
Measure M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
M 
(SD) 
n 
d 
[95% CI] 
d 
[95% CI] 
Self-efficacy with asthma 
managementb 
134.29 136.65 135.63 140.26 137.27 128.95 0.35 0.63 
(27.37) (33.64) (39.64) (23.16) (20.13) (37.36) [-0.26-0.95] [0.00-1.27] 
 24 20 19 23 22 21   
Self-efficacy with asthma 
behaviour managementc 
184.83 187.75 186.21 182.74 189.32 173.62 -0.02 0.24 
(36.76) (41.34) (47.34) (41.82) (21.24) (47.37) [-0.62-0.58] [-0.38-0.86] 
 24 20 19 23 22 21   
Extent of asthma 
behaviour difficultiesd 
46.29 47.30 43.84 47.30 48.50 43.33 0.10 0.05 
(23.05) (28.23) (21.61) (19.77) (24.64) (23.71) [-0.51-0.70] [-0.57-0.66] 
 24 20 19 23 22 21   
Number of asthma 
episodes per weeke 
2.50 2.08 0.69 2.41 2.75 2.53 0.22 0.80 
(3.37) (2.55) (1.03) (2.47) (2.41) (2.95) [-0.42-0.85] [0.15-1.46] 
 20 18 18 22 21 21   
Number of moderate-
severe episodes per weekf 
1.61 0.89 0.90 1.48 1.38 1.36 0.28 0.54 
(2.08) (1.08) (1.70) (1.40) (1.27) (1.23) [-0.35-0.90] [-0.10-1.18] 
 22 18 19 22 21 21   
Competence with asthma 
management (observed)g 
2.60 3.21 3.00 2.78 2.64 2.50 0.35 0.22 
(1.29) (1.13) (1.06) (1.00) (1.22) (1.15) [-0.26-0.95] [-0.42-0.85] 
 25 19 17 23 22 20   
Abbreviations: T1, time 1 (baseline); T2, time 2 (post-intervention); T3, time 3 (6-month follow-up); CI, confidence interval. 
a
Effect sizes (Cohen’s d) represent the T1-T2 change in Intervention group minus the T1-T2 change in Care as Usual group, divided by the 
pooled T1 standard deviation for the measure. 
b
Asthma Parent Tasks Checklist - Confidence scores (possible range 17-170). 
c
Asthma 
Behaviour Checklist – Confidence scores (possible range 22-220). 
d
Asthma Behaviour Checklist – Extent scores (possible range 22-154). 
e
Figures indicate mean number of asthma episodes per week during each 2-week monitoring period. 
f
Figures indicate mean number of 
days per week where an asthma episode lasted >2 hours, interfered with play / school / sleep, or led to shortening of normal activity, 
seeing a doctor, or going to hospital. 
g
Possible scores 0-5.
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Table 4. Means and standard deviations for health-related quality of life outcomes by treatment condition, and effect sizes 
 Intervention (n=52) Care as Usual (n=55) Effect sizea 
T1 T2 T3 T1 T2 T3 T1-T2 T1-T3 
 n=51 n=44 n=42 n=55 n=51 n=45   
Measure M 
(SD) 
M 
(SD) 
M 
(SD) 
M 
(SD) 
M 
(SD) 
M 
(SD) 
d 
[95% CI] 
d 
[95% CI] 
 
Child HRQLb  68.63 73.27 75.51 71.11 74.84 74.75 0.03 0.15 
 (13.85) (14.94) (15.56) (14.56) (14.99) (15.36) [-0.38-0.43] [-0.27-0.57] 
         
Parent HRQLc 59.78 67.27 70.57 63.05 65.20 63.64 0.23 0.57 
 (17.03) (21.62) (18.96) (19.18) (20.51) (20.32) [-0.17-0.64] [0.14-1.00] 
         
Family HRQLd 53.62 62.00 65.92 61.88 66.12 62.22 0.08 0.53 
 (23.58) (28.87) (21.03) (22.29) (20.80) (23.63) [-0.32-0.48] [0.11-0.96] 
 
Abbreviations: T1, time 1 (baseline); T2, time 2 (post-intervention); T3, time 3 (6-month follow-up); CI, confidence interval. 
a
Effect sizes (Cohen’s d) represent the T1-T2 change in Intervention group minus the T1-T2 change in Care as Usual group, 
divided by the pooled T1 standard deviation for the measure. 
b
Pediatric Quality of Life Generic Core Scale (possible range 0-
100). 
c
Parent HRQL Summary score (possible range 0-100). 
d
Family Functioning Summary score (possible range 0-100). 
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Table 5. Intervention effects for parent and child outcomes by treatment condition 
 
Model 1 2 3 4  
 
Estimate of fixed effects:  
timea 
Estimate of fixed effects: 
time x condition interactiona,b 
Estimate of fixed effects:  
time (separate by condition)a 
Comparisonc 
Intervention Care as Usual  
Measure β F df p β  F df p β p β p t p 
            
Self-efficacy for illness managementd            
    Eczema 0.28 14.30 74.26 <.001 0.37 7.04 73.78   .010 0.48 <.001 0.11   .19 2.55   .01 
    Asthma -2.95 0.83 37.55   .37  3.93 0.38 36.56   .54 -0.69   .89 -4.87   .21 -0.67   .50 
    
 
          
Self-efficacy for behaviour managemente 
 
          
    Eczema 10.51 19.92 81.00 <.001 18.04 18.28 77.96 <.001 20.24 <.001 2.21   .45 -4.31 <.001 
    Asthma -2.53 0.38 42.52   .54 3.06 0.14 42.47   .71 -2.43   .74 -4.03   .46 -0.18   .86 
    
 
          
Extent of behaviour difficultiesf 
 
          
    Eczema -9.61 42.24 150.32 <.001 -8.93 12.16 279.33   .001 -14.24 <.001 -5.31   .005 3.50 <.001 
    Asthma -2.38 3.06 85.29   .08 -0.23 0.01 148.92   .92 -2.24   .11 -1.85   .32 0.17   .87 
    
 
          
Health-related quality of lifeg 
 
          
    Child 2.68 16.74 90.10 <.001 1.02 0.60 89.94   .44 3.24   .001 2.20   .02 3.24   .44 
    Parent 2.79 8.85 196.19 
  .003 4.84 6.87 195.51   .009 5.33 <.001 0.47   .71 -2.62   .01 
    Family 2.97 6.99 192.36 
  .009 5.78 6.83 191.42   .01 6.02   .002 0.20   .87 -2.58   .01 
    
 
   
 
      
Symptom severity   
 
   
 
      
    Eczemah -1.49 18.17 73.61 <.001 -1.34 3.89 73.52   .052 -2.25 <.001 -0.89   .06 1.99   .049 
    Asthma   
 
   
 
      
    - episodesi -0.36 2.18 76.73   .14 -1.02 4.79 76.69 
  .03 -0.89   .01 0.14   .68 -2.01   .03 
    - mod-severej -0.27 5.62 70.51 
  .02 -0.42 3.39 70.20   .07 -0.49   .009 -0.07   .62 1.82   .08 
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Competence with illness management (observed)   
 
      
    Eczemak -0.02 0.01 136.61   .92 0.78 2.92 136.85 
  .09 0.38   .21 -0.37   .26 -1.69   .09 
    Asthmal 0.01 0.00 84.81   .96 0.29 2.09 84.80   .15 0.18   .27 -0.13   .32 -1.50   .14 
    
 
          
a
β = estimated regression coefficients from mixed-model repeated-measures linear regressions. 
b
Figures indicate the estimated change in 
the Intervention group from pre-intervention to post-intervention follow-up relative to the Care as Usual group. 
c 
Test of the difference 
between Intervention and Care as Usual groups for rate of change (estimated regression coefficients); degrees of freedom = 44 for asthma 
variables, 81 for eczema variables, 103 for all other variables. 
d
Modified Parental Self-Efficacy with Eczema Care Index (PASECI) (possible 
range 0-10); Asthma Parent Tasks Checklist - Confidence scores (possible range 17-170). 
e
Eczema Behaviour Checklist – Confidence scores 
(possible range 25-250);
 
Asthma Behaviour Checklist – Confidence scores (possible range 22-220). 
f
Eczema Behaviour Checklist – Extent 
scores (possible range 25-175); Asthma Behaviour Checklist – Extent scores (possible range 22-154). 
g
Pediatric Quality of Life Generic Core 
Scale (possible range 0-100); Parent HRQL Summary score (possible range 0-100); Family Functioning Summary score (possible range 0-100). 
h
Patient-Oriented Eczema Measure (possible scores 0-28).
i 
Figures indicate mean number of asthma episodes per week during each 2-week 
monitoring period. 
j
Figures indicate mean number of days per week where an asthma episode lasted >2 hours, interfered with play / school 
/ sleep, or led to shortening of normal activity, seeing a doctor, or going to hospital. 
k
Possible scores 0-11.
l
 Possible scores 0-5. 
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Table 6. Intervention effects for symptom severity by treatment group and corticosteroid prescription 
 
Model 1 2 3 4  
 
Estimate of fixed effects:  
timea 
Estimate of fixed effects: 
time x condition interactiona,b 
Estimate of fixed effects:  
time (separate by condition)a 
Comparisonc 
Intervention Care as Usual  
Measure β F df p β  F df p β p β p t p 
 
 
          
Eczema symptom severityd 
 
          
    Topical 
corticosteroid 
-1.69 16.82 53.45 <.001 -2.43 10.01 52.76 .003 -3.16 <.001 -0.77 .14 3.18 .002 
    No topical 
corticosteroid 
-1.00 2.22 44.20 .14 0.70 0.27 43.94 .61 -0.75 .40 -1.35 .20 -0.44 .67 
               
Asthma episodes/weeke              
    Preventer -0.43 1.60 51.18 .21 -1.54 5.64 50.63 .02 -1.29 .02 0.25 .56 2.38 .03 
    No preventer -0.16 0.57 22.38 .46 -0.05 0.01 19.51 .92 -0.16 .59 -0.14 .69 0.05 .96 
               
Moderate-severe asthma episodes – days/weekf           
    Preventer -0.40 6.02 46.68 .02 -0.63 4.03 46.88 .051 -0.75 .01 -0.12 .54 1.96 .06 
    No preventer -0.02 0.02 21.74 .88 -0.14 0.34 19.72 .56 -0.07 .69 0.07 .71 0.56 .58 
    
 
          
a
β = estimated regression coefficients from mixed-model repeated-measures linear regressions. 
b
Figures indicate the estimated change in 
the Intervention group from pre-intervention to post-intervention follow-up relative to the Care as Usual group. 
c 
Test of the difference 
between Intervention and Care as Usual groups for rate of change (estimated regression coefficients); degrees of freedom: asthma with 
preventer = 27, no preventer = 12, eczema with topical corticosteroid = 55, no topical corticosteroids = 22. 
d
Patient-Oriented Eczema 
Measure. 
e
Mean number of asthma episodes per week during each 2-week monitoring period. 
f
Mean number of days per week where an 
asthma episode lasted >2 hours, interfered with play/school/sleep, or led to shortening of normal activity, seeing a doctor, or going to 
hospital.  
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Figure 2. Plots of regression slopes for change over time for eczema severity 
(mean POEM scores) by treatment group and whether topical steroids were 
prescribed by the child’s doctor. T1 = time 1 (baseline); T2 = time 2 (post-
intervention); T3 = time 3 (6-month follow-up). 
 
 
 
Figure 3. Plots of regression slopes for change over time for episodes of asthma 
per week by treatment group and whether a preventer was prescribed by the 
child’s doctor. T1 = time 1 (baseline); T2 = time 2 (post-intervention); T3 = 
time 3 (6-month follow-up). 
 
 
